Features of the course and treatment of JIA-associated uveitis
DOI:
https://doi.org/10.31288/oftalmolzh201922227Keywords:
uveitis, juvenile idiopathic arthritisAbstract
Purpose: To investigate the features of the clinical course of and the state of eye care for patients with juvenile idiopathic arthritis (JIA)-associated uveitis (JIA-U).
Materials and Methods: We analyzed the results of monitoring 121 patients aged 7 to 18 years with JIA. Twenty one (17.35%) of these had uveitis.
Results: In 17 (80.95%) of the examined JIA-U patients, JIA onset age was younger than 6 years, and mean JIA onset age was significantly younger than in JIA patients without uveitis (2.89±0.26 years vs 6.43±0.4 years, р<0.05). Most (85.7%) JIA-U patients were asymptomatic. Chronic keratic precipitates and posterior synechiae were found in 38.09% and 42.85%, respectively, of cases. Uveal cataract was the most common complication (57.14%), followed by corneal degeneration (33.33%), macular edema (28.57%), ocular hypertension/ secondary glaucoma (19.05%), optic nerve edema (14.28%), hypotony (14.28%), vitreous fibrosis (9.52%), and retinal detachment (4.76%). The frequency of administration of biologics was 57.14%. The mean time from disease onset to administration of biologics in our JIA-U patients (2.67±0.79 years) was 2.5 times less than the value for JIA-U patients from all over Ukraine (6.9 years), indicating that biologics were timely administered.
Conclusion: Patients with the condition are commonly asymptomatic and have frequent ocular complications, with uveal cataract being the most common, followed by corneal degeneration and macular edema.
References
1.Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016 Apr;14(1):27.https://doi.org/10.1186/s12969-016-0088-2
2.Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015;11:338-48.https://doi.org/10.1038/nrrheum.2015.20
3.Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis. F1000Prime Rep. 2014 Jun;6:41.https://doi.org/10.12703/P6-41
4.Mérida S, Palacios E, Navea A, Bosch-Morell F. New Immunosuppressive Therapie sin Uveitis Treatment. Int J Mol Sci. 2015 Aug;16(8):18778-95.https://doi.org/10.3390/ijms160818778
5.Jabs DA. Immunosuppression for the Uveitides. Ophthalmology. 2018 Feb;125(2):193-202.https://doi.org/10.1016/j.ophtha.2017.08.007
6.Tugal-Tutkun І. Pediatric Uveitis. J Ophthalmic Vis Res. 2011;6(4):259-69.
7.Smith JA, Mackensen F, Sen HN et al. Epidemiology and course of disease in childhood uveitis. Ophthalmologу. 2009 Aug;116(8):1544-51.https://doi.org/10.1016/j.ophtha.2009.05.002
8.Ramanan AV, Dick AD, Benton D et al., SYCAMORE Trial Management Group. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014 Jan;15:14.https://doi.org/10.1186/1745-6215-15-14
9.Ftrrara M, Eggenschwiler L, Stephenson A et al. The Challenge of Pediatric Uveitis: Tetriary Referral Center Experience in the United States. Ocul Immunol Inflamm. 2018 Jan;15:1-8.
10.Foeldvari I, Walscheid K, Heiligenhaus A. Uveitis in juvenile idiopathic arthritis. Z Rheumatol. 2017 Oct;76(8):664-72.https://doi.org/10.1007/s00393-017-0360-y
11.Heiligenhaus A, Niewerth M, Ganser G et al. Prevalence and complications of uveitis in juvenile idiopathiс arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology. 2007; 46:1015-1019.https://doi.org/10.1093/rheumatology/kem053
12.Cosickic A, Halilbasic M, Selimovic A, Avdagic H. Uveitis Associated with Juvenile Idiopathic Arthritis, our Observations. Med Arch. 2017 Feb; 71(1): 52-5.https://doi.org/10.5455/medarh.2017.71.52-55
13.Angeles-Han ST, Rabinovich CE. Uveitis in children. Curr Opin Rheumatol. 2016 Sep;28(5):544-9.https://doi.org/10.1097/BOR.0000000000000316
14.Heiligenhaus A, Minden K, Foll D, Pleyer U. Uveitis in juvenile idiopathic arthritis. Dtsch Arztebl Int 2015; 112: 92-100.https://doi.org/10.3238/arztebl.2015.0092
15.Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003 Jul;87(7):879-84.https://doi.org/10.1136/bjo.87.7.879
16.Cann M., Ramanan AV., Crawford A. et al. Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. Pediatr Rheumatol Online J. 2018 Aug;16(1):51.https://doi.org/10.1186/s12969-018-0266-5
17.Hersh AO, Cope S, Bohnsack JF et al. Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis. Ocul Immunol Inflamm. 2018;26(4):642-50.
18.Dajee KP, Rossen JL, Bratton ML et al. A 10-year review of pediatric uveitis at a Hispanic dominated tertiary pediatric ophthalmic clinic. Clin Ophthalmol. 2016 Aug;10:1607-12.https://doi.org/10.2147/OPTH.S96323
19.Gregory AC, Kaçmaz RO, Foster CS et al. Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013 Jan;120(1):186-92.https://doi.org/10.1016/j.ophtha.2012.07.052
20.Ramanan AV, Dick AD, Jones AP et al. SYCAMORE Study Group. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017 Apr;376(17):1637-46.https://doi.org/10.1056/NEJMoa1614160
21.Davies R, Carrasco R, Foster HE et al. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS). Semin Arthritis Rheum. 2016 Oct; 46(2): 190-195.https://doi.org/10.1016/j.semarthrit.2016.06.001
22.Cecchin V, Zannin ME, Ferrari D et al. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. The Journal of Rheumatology. 2018 Aug; 45 (8) 1167-72; https://doi.org/10.3899/jrheum.171006
23.Quartier P, Baptiste A, Despert V. et al. ADJUVITE Study Group. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018 Jul;77(7):1003-11.https://doi.org/10.1136/annrheumdis-2017-212089
24.Constantin T, Foeldvari I, Anton J et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018 Aug;77(8):1107-17.https://doi.org/10.1136/annrheumdis-2018-213131
25.Angeles-Han ST, McCracken C, Yeh S, et al. Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis. Pediatr Rheumatol Online J. 2015 Jun;13:19.https://doi.org/10.1186/s12969-015-0018-8
26.Angeles-Han ST, Pelajo CF, Vogler LB et al. CARRA Registry Investigators. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritisand Rheumatology Research Alliance. J Rheumatol. 2013 Dec;40(12):2088-96.https://doi.org/10.3899/jrheum.130302
27.Paroli MP, Abbouda A, Restivo L et al. Juvenile idiopathic arthritis-associated uveitis at an Italian tertiary referral center: clinical features and complications. Ocul Immunol Inflamm. 2015 Feb;23(1):74-81.https://doi.org/10.3109/09273948.2013.855798
28.Skarin A, Elborgh R, Edlund E, Bengtsson-Stigmar E. Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study. Ocul Immunol Inflamm. 2009;17(2):104-8.https://doi.org/10.1080/09273940802650398
29.Stroh IG, Moradi A, Burkholder BM, et al. Occurrence of and Risk Factors for Ocular Hypertension and Secondary Glaucoma in Juvenile Idiopathic Arthritis-associated Uveitis. Ocul Immunol Inflamm. 2017 Aug;25(4):503-512.https://doi.org/10.3109/09273948.2016.1142573
30.Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1771-4.https://doi.org/10.1002/art.11156
31.Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405-13.https://doi.org/10.1002/art.38615
32.Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018 Jun; 77(6): 819-828.
33.Henderson LA, Zurakowski D, Angeles-Han ST et al. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016; 14: 9.https://doi.org/10.1186/s12969-016-0069-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 М. В. Панченко, Н. С. Шевченко, М. В. Дем’яненко, О. М. Гончарь, Л. Г. Авілова
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
